Pulmonary Embolism

This channel includes news and new technology innovations for Pulmonary Embolism. This condition occurs when an artery in the lungs is blocked, usually caused by a blood clot.

Study data show clinically meaningful impact on quality of life and disease severity, even in the most complex patients

News | Venous Therapies

ABRE Clinical Study 36-Month Data Shows Sustained Effectiveness of Abre Venous Self-Expanding Stent System

October 14, 2022 — Medtronic, a global leader in medical technology, announced the 36-month final results from the ABRE ...

October 14, 2022

Anthos Therapeutics has announced that Abelacimab has received FDA Fast Track Designation for the prevention of stroke and systemic embolism in patients with atrial fibrillation.

News | Stroke

Anthos Therapeutics Announces Abelacimab Received FDA Fast Track Designation for the Prevention of Stroke and Systemic Embolism in Patients with AFib

September 13, 2022 — Anthos Therapeutics, a clinical-stage biotechnology company developing innovative therapies for ...

September 13, 2022

The Pulmonary Hypertension Association (PHA) joins more than 80 organizations around the world on Thursday, May 5, to recognize World PH Day.

News | Heart Failure

World PH Day Raises Awareness for Pulmonary Hypertension’s Global Impact

April 20, 2022 – The Pulmonary Hypertension Association (PHA) joins more than 80 organizations around the world on ...

April 20, 2022

Inari Medical, Inc. has announced that the first patient has been enrolled in PEERLESS, a prospective, randomized controlled trial comparing the outcomes of patients with intermediate-high risk pulmonary embolism (PE) treated with the FlowTriever system versus catheter-directed thrombolysis (CDT).

News | Pulmonary Embolism

Inari Medical Announces First Patient Enrolled in the PEERLESS Trial

February 16, 2022 – Inari Medical, Inc. has announced that the first patient has been enrolled in PEERLESS, a ...

February 16, 2022

Pulmonary embolisms are dangerous, lung-clogging blot clots. In a pilot study, scientists at the Icahn School of Medicine at Mount Sinai showed for the first time that artificial intelligence (AI) algorithms can detect signs of these clots in electrocardiograms (EKGs), a finding which may one day help doctors with screening.

News | Pulmonary Embolism

Could EKGs Help Doctors Use AI to Detect Pulmonary Embolisms?

February 14, 2022 — Pulmonary embolisms are dangerous, lung-clogging blot clots. In a pilot study, scientists at the Ica ...

February 14, 2022

Videos | Artificial Intelligence

VIDEO: Examples of Artificial Intelligence PE Response Team Apps

Here are two examples of artificial intelligence (AI) driven pulmonary embolism (PE) response team apps featured by ...

January 13, 2022

News | Thrombectomy Devices

Akura Medical Closes $25 Million in A1 Financing to Develop New Thrombectomy System

January 10, 2022 – Akura Medical Inc., a Shifamed portfolio company, announced the closing of its $25 million Series A1 ...

January 10, 2022

The Viz.AI pulmonary embolism response team (PERT) app that uses AI to detect PE on images before they go into PACS, alerts the PERT team members and provides a mobile platform to message, review images and other patient data. Photo by Dave Fornell

Feature | Artificial Intelligence | By Dave Fornell, DAIC Editor

AI Can Facilitate Automated Activation of Pulmonary Embolism Response Teams

Artificial intelligence (AI) has found a unique niche to help automate the activation of acute care teams for pulmonary ...

December 09, 2021

Boston Scientific Corp. has commenced enrollment in the HI-PEITHO clinical trial, a collaborative research study with the Pulmonary Embolism Response Team (PERT) Consortium and the University Medical Center of the Johannes Gutenberg University of Mainz comparing use of the EkoSonic Endovascular System in combination with anticoagulation to anticoagulation alone for the treatment of acute, intermediate-high-risk pulmonary embolism (PE).

News | Pulmonary Embolism

Study Compares Interventional Pulmonary Embolism Therapy in Combination With Anticoagulation to Anticoagulation Alone

August 9, 2021 — Boston Scientific Corp. has commenced enrollment in the HI-PEITHO clinical trial, a collaborative ...

August 09, 2021

An example of Viz.AI's pulmonary embolism AI application and mobile alert to the physician on-call. Viz.AI and Avicenna.AI Partner to Launch Artificial Intelligence Care Coordination for Pulmonary Embolism and Aortic Disease

News | Artificial Intelligence

Viz.AI and Avicenna.AI Partner to Launch Artificial Intelligence Care Coordination for Pulmonary Embolism and Aortic Disease

July 21, 2021 — Artificial intelligence (AI) medical imaging vendors Viz.AI and Avicenna.AI have partnered to enable ...

July 21, 2021

Avicenna.AI announces the introduction of Cina Chest, including AI tools for detection and emergency triage of pulmonary embolism and aortic dissection.

News | Artificial Intelligence

AI Triage Solution for PE and Aortic Dissection Receives FDA Clearance and CE Mark

June 3, 2021 — Medical imaging AI specialist Avicenna.AI announced that it has received certification in the United ...

June 07, 2021

Videos | Coronavirus (COVID-19)

VIDEO: Antithrombotic Prophylaxis in COVID-19 Patients

Behnood Bikdeli M.D., a cardiologist at the Brigham and Women’s Hospital, Harvard Medical School, Boston, offers an ...

April 01, 2021

Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) can potentiate all 3 sides of Virchow’s Triad of coagulopathy, including endothelial dysfunction, blood flow stasis, and hypercoagulability. Angiotensin-converting enzyme-2 (ACE-2)–dependent viral entry and the virus-induced inflammatory response can lead to endothelial dysfunction. Clotting Prevention in COVID-19 Patients, Thrombosis Prevention in COVID-19 Patients, Preventing blood clots in COVID-19 patients

Feature | Antiplatelet and Anticoagulation Therapies | By Dave Fornell, Editor

Overview of Trials for Anticoagulation Therapy for COVID-19 Patients

A comprehensive review or more than 80 randomized controlled trials (RCTs) investigating how to best manage optimal ...

March 22, 2021

The FDA has granted 510(k) clearance for the Inari Medical Inc. FlowTriever system for the treatment of clot in transit (CIT) in the right atrium. FlowTriever is the first thrombectomy system not requiring a cardiopulmonary bypass circuit to be FDA cleared for blood clots in the right atrium.

News | Thrombectomy Devices

FDA Clears Inari Medical FlowTriever System for Treatment of Right Atrial Clot in Transit

January 8, 2021 — The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the Inari Medical Inc ...

January 08, 2021

Thrombus formation in the aortic arch in a 46-year-old COVID patients in the ICU. Three trials are underway to find which anticoagulant strategy is best to treat moderate and critically ill patients where COVID-causes venous thrombo-embolism (VTE) is a major cause of complications. Image courtesy of Margarita Revzin et al.

Feature | Coronavirus (COVID-19)

NIH Pauses Anticoagulant Trial For Critically Ill COVID-19 Patients

December 23, 2020 — Three clinical trial platforms working together to test the effects of full doses of anticoagulants ...

December 23, 2020